article thumbnail

How much is Rexulti without insurance?

The Checkup by Singlecare

Without insurance coverage, Rexulti’s average price is around $1,926 for a 30-day supply. In August 2022, the FDA approved a generic version of brexpiprazole for schizophrenia as an adjunctive therapy to antidepressants for treating MDD. Is Rexulti covered by insurance? How much does Rexulti cost without insurance?

article thumbnail

Fragmented Policy, Insurance Landscape Challenges Newly Approved Vaccines

Drug Topics

In 2023, the FDA approved six vaccines, including several important firsts. Innovation in the vaccine area continues. But they face a difficult landscape where federal policies dictate coverage.

Vaccines 184
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How much is Mounjaro without insurance?

The Checkup by Singlecare

Is Mounjaro covered by insurance? | How much does Mounjaro cost without insurance? | How to get Mounjaro without insurance Mounjaro (tirzepatide) is a brand-name prescription drug FDA-approved to control blood sugar levels in people with Type 2 diabetes. Only some insurance providers will cover it. mL of 5 mg/0.5

article thumbnail

How much is Wegovy without insurance?

The Checkup by Singlecare

Is Wegovy covered by insurance? | How much does Wegovy cost without insurance? | How to get Wegovy without insurance Wegovy is a brand-name prescription drug used along with a reduced-calorie diet and physical activity for chronic weight management. Is Wegovy covered by insurance? mL of 0.25 mL of 5 mg/0.5 mL of 5 mg/0.5

article thumbnail

FDA's Califf calls on insurers to help providers participate in critical clinical drug trials

Fierce Healthcare

FDA's Califf calls on insurers to help providers participate in critical clinical drug trials rking Thu, 03/16/2023 - 11:55

article thumbnail

STAT+: Califf criticizes insurers for doing too little on drug research

STAT

WASHINGTON — FDA Commissioner Robert Califf wants private insurers to chip in on doing post-approval clinical research on drugs. It’s a new request from the agency chief, who’s long pushed to find new ways to test drugs. ” Continue to STAT+ to read the full story…

article thumbnail

STAT+: How digital therapeutics companies are improvising when insurance coverage isn’t guaranteed

STAT

Pear received Food and Drug Administration clearance for its app treating substance use disorders and insomnia but insurers mostly refused to cover the novel treatments. The bankruptcy of Pear Therapeutics last year proved that selling software-based treatments like drugs is harder than anticipated.